tiprankstipranks
Inovio’s INO-3107 shows surgery reduction efficacy in papillomatosis
The Fly

Inovio’s INO-3107 shows surgery reduction efficacy in papillomatosis

Innovio announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis – RRP – in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 patients – 91% – saw a reduction in surgical interventions in the year following initial treatment. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior. In the year prior to treatment, the number of surgical interventions for these 11 patients ranged between 2 and 8, and the median was 5. INO-3107 was well-tolerated and immunogenic among patients in the second cohort. The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022. INO-3107 was well-tolerated in the trial, with all 11 patients completing the trial follow-up.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on INO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles